Cadrenal Therapeutics (CVKD) Current Assets (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Current Assets of $2.9 million for Q1 2026, down 33.9% sequentially from $4.3 million in Q4 2025, and down 64.06% YoY from $7.9 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Current Assets (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Current Assets for 5 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Current Assets fell 64.06% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 64.06% YoY) and the FY2025 annual result came in at $4.3 million, down 57.29% from the prior year.
- Current Assets fell to $2.9 million in Q1 2026 per CVKD's latest filing, from $4.3 million in the prior quarter.
- Over five years, Current Assets peaked at $10.1 million in Q4 2024 and troughed at $727596.0 in Q4 2022.
- A 5-year average of $5.6 million and a median of $5.1 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2026: Current Assets jumped 1067.15% in 2023, then plunged 64.06% in 2026.
- Over 5 years, Current Assets stood at $727596.0 in 2022, then surged by 1067.15% to $8.5 million in 2023, then increased by 19.08% to $10.1 million in 2024, then plunged by 57.29% to $4.3 million in 2025, then slumped by 33.9% to $2.9 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $2.9 million, $4.3 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 1.76 Bn |
| 10 | Cadrenal Therapeutics | 4.57 Mn | 2.17 Mn | - | 5.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.58 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | 5.97 Mn |
| Mar 31, 2025 | 7.94 Mn |
| Dec 31, 2024 | 10.11 Mn |
| Sep 30, 2024 | 4.67 Mn |
| Jun 30, 2024 | 5.44 Mn |
| Mar 31, 2024 | 7.03 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Sep 30, 2023 | 9.28 Mn |
| Jun 30, 2023 | 3.52 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Dec 31, 2022 | 727,596.00 |